| CTRI Number |
CTRI/2025/02/079932 [Registered on: 04/02/2025] Trial Registered Prospectively |
| Last Modified On: |
03/07/2025 |
| Post Graduate Thesis |
No |
| Type of Trial |
Interventional |
|
Type of Study
|
Drug |
| Study Design |
Single Arm Study |
|
Public Title of Study
|
Testing Bumsuit Baby Products to Check for Skin Irritation and Allergies in Healthy Children. |
|
Scientific Title of Study
|
A Non-Randomized, Open-Label, Single-Center Study To Evaluate The Irritation And Sensitization Potential Of Bumsuit Baby Products In Healthy Volunteer Children Using The Human Repeat Insult Patch Test (HRIPT). |
| Trial Acronym |
Nil |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| CTSRS/2429 Version No. 1.0 Dated 13/Dec/2024 |
Protocol Number |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Dr Uday Kumar S |
| Designation |
Principal Investigator |
| Affiliation |
Currex Hospital Bangalore |
| Address |
Currex Hospital, No.55-56, Seegehalli Main Road, Bhoo Samartha Layout,
Bangalore KARNATAKA 560059 India |
| Phone |
6364898825 |
| Fax |
|
| Email |
pi.clinicaltrial@gmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
Ms Sathyavathi L M |
| Designation |
HOD-Clinical Operations |
| Affiliation |
Samahitha Research Solutions |
| Address |
Currex Hospital, No.55-56, Seegehalli Main Road, Bhoo Samartha Layout
Bangalore KARNATAKA 560069 India |
| Phone |
09739001749 |
| Fax |
|
| Email |
satyalm@samahitha.com |
|
Details of Contact Person Public Query
|
| Name |
Ms Arpita Malgi |
| Designation |
Team Lead - Clinical Operations |
| Affiliation |
Samahitha Research Solutions |
| Address |
Clinical Research Unit No.1204, Ashva, 2nd Floor, 26th Main,
Jayanagar 9th Block, Bangalore
Bangalore
Bangalore KARNATAKA 560069 India |
| Phone |
06364898825 |
| Fax |
|
| Email |
arpita@samahitha.com |
|
|
Source of Monetary or Material Support
|
| Kamson Healthcare Pvt. Ltd.
Sy.No 546,AA1,AA2, Nandigam ( Village & Mandal)
Rangareddy Dist., Telangana,India -509228 |
|
|
Primary Sponsor
|
| Name |
Kamson Healthcare Pvt. Ltd. |
| Address |
Sy.No 546,AA1,AA2, Nandigam ( Village & Mandal)
Rangareddy Dist., Telangana, India -509228 |
| Type of Sponsor |
Pharmaceutical industry-Indian |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Uday Kumar S |
Currex Hospital |
No.55-56, Seegehalli Main Road, Bhoo Samartha Layout,
Seegehalli, KS Halli, Bengaluru Bangalore KARNATAKA |
06364898825
pi.clinicaltrial@gmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| Pranav Diabetes Center Ethics Committee |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Healthy Human Volunteers |
To Evaluate The Irritation And Sensitization Potential Of Bumsuit Baby Products In Healthy Volunteer Children Using The Human Repeat Insult Patch Test (HRIPT). |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Intervention |
Bumsuit Baby Cream, Bumsuit Baby Lotion, Bumsuit Baby Massage Oil, and Bumsuit Baby Shampoo |
The products will be applied in a patch chamber (0.04 ml) to evaluate skin irritancy and allergic sensitization. The duration of treatment will be 24 hours, with a one-hour window, for a period of 14 days (with an additional one-day window). |
| Comparator Agent |
NA |
NA |
|
|
Inclusion Criteria
|
| Age From |
5.00 Year(s) |
| Age To |
18.00 Year(s) |
| Gender |
Both |
| Details |
1. Healthy volunteers aged 5 to 18 years.
2. Subjects with no clinically significant dermatological conditions e.g., eczema, psoriasis.
3. Subjects whose guardians/parents have provided Informed Consent.
4. Willing to adhere to study restrictions no use of other skincare products in the test area. |
|
| ExclusionCriteria |
|
|
Method of Generating Random Sequence
|
Not Applicable |
|
Method of Concealment
|
On-site computer system |
|
Blinding/Masking
|
Open Label |
|
Primary Outcome
|
| Outcome |
TimePoints |
| Measured by visual assessment and scoring (e.g., Erythema, Edema) using a standardized grading scale at various time points during the induction phase. |
Day 0, Day 1, Day 2, Day 3 and Day 7, Day 14 and Day 21 |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
| Evaluated through participant-reported outcomes regarding skin discomfort, dryness, or other adverse effects through a standardized questionnaire. |
Day 0, Day 1, Day 2, Day 3 and Day 7, Day 14 and Day 21 |
|
|
Target Sample Size
|
Total Sample Size="24" Sample Size from India="24"
Final Enrollment numbers achieved (Total)= "24"
Final Enrollment numbers achieved (India)="24" |
|
Phase of Trial
|
Phase 3 |
|
Date of First Enrollment (India)
|
11/02/2025 |
| Date of Study Completion (India) |
28/02/2025 |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Date Missing |
|
Estimated Duration of Trial
|
Years="0" Months="0" Days="21" |
|
Recruitment Status of Trial (Global)
|
Not Applicable |
| Recruitment Status of Trial (India) |
Completed |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
Brief Summary
Modification(s)
|
Background and Introduction The early stages of life are recognized as critical for the healthy development of children, and proper skincare plays an essential role in promoting long-term well-being. During childhood and adolescence, the skin undergoes various changes, making it necessary for skincare products to be both effective and safe. Bumsuit Baby Products, commonly used to moisturize and protect the skin, are carefully evaluated to ensure they do not cause irritation or sensitization, particularly in children and adolescents, whose skin is more sensitive than that of adults. The study participants, representing a wide range of skin types, helped determine whether the products are suitable for use in children and adolescents. This research provided essential data to confirm the safety profile of Bumsuit Baby Products, ensuring they meet safety standards and can be used confidently by parents, caregivers, and healthcare professionals. Purpose of the Study The purpose of the study was to evaluate the safety and efficacy of Bumsuit Baby Products in moisturizing and protecting the sensitive skin of children and adolescents. By including participants with diverse skin types, the study aimed to confirm that these products did not cause irritation or sensitization and met established safety standards. The findings provided critical data to support the safe and confident use of Bumsuit Baby Products by parents, caregivers, and healthcare professionals for maintaining healthy skin in young individuals. Results The study was conducted over a 21-day period for each participant.The study enrolled 24 healthy children aged between 5 to 18 years. All 24 participants completed the study without any discontinuations, resulting in a 100% subject completion and compliance rate. The mean (SD) age of the participants was 11.95 (4.14) years. Primary Outcomes: Dermatological assessments conducted using the Draize scale showed that none of the participants exhibited any signs of erythema (redness), edema (swelling), dryness, or skin flaking at any of the evaluated time points. All four products Bumsuit Baby Cream, Lotion, Massage Oil, and Shampoo, were rated as non-irritating and well-tolerated. Secondary Outcomes: Self-assessments by participants (or their guardians) confirmed the absence of any sensations of burning, itching, tingling, scaling, or discomfort throughout the 21-day study period. No acute or delayed hypersensitivity reactions were reported. Safety Profile: No adverse events (AEs) or serious adverse events (SAEs) were observed. There were no protocol deviations or dropouts. |